Disc Med­i­cine claims PhII win for re­pur­posed ex-Roche drug in rare blood dis­or­der

When Disc Med­i­cine closed a $62.5 mil­lion raise led by Bain Cap­i­tal ear­li­er this year, the biotech’s CEO John Quisel point­ed to the stream of clin­i­cal read­outs in blood dis­or­ders it is ex­pect­ing as the im­pe­tus.

Now, it’s out­lin­ing the first of those da­ta — with an open-la­bel Phase II tri­al pro­vid­ing what it calls the first clin­i­cal ev­i­dence sup­port­ing its lead can­di­date in a rare dis­ease that makes pa­tients ex­tra-sen­si­tive to sun­light, re­sult­ing in ex­treme pain.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER